Extended-release niacin/laropiprant lipid-altering consistency across patient subgroups.

Abstract

BACKGROUND:

In patients with primary hypercholesterolemia or mixed dyslipidemia, extended-release niacin/laropiprant (ERN/LRPT) improves key lipid parameters associated with increased atherosclerotic coronary heart disease (CHD) risk.

AIM:

This analysis examined data from four Phase III, randomised, double-blind trials to determine the consistency of ERN/LRPT's lipid-altering efficacy among subgroups of patients.

METHODS:

Data from four Phase III, randomised, double-blind trials of ERN/LRPT were analysed to determine the consistency of ERN/LRPT's lipid-altering efficacy among subgroups of gender, race (white, non-white), region (US, ex-US), baseline age (<65, ≥65 years), use of statin therapy, CHD risk status (low, multiple, high) and type of hyperlipidemia (primary hypercholesterolemia, mixed dyslipidemia), as well as across baseline low-density lipoprotein cholesterol (LDL-C), high-density lipoprotein cholesterol (HDL-C) and triglyceride (TG) levels. End-points included the per cent change from baseline in LDL-C, HDL-C and TG levels. Consistency of the treatment effects on LDL-C, HDL-C and TG across subgroups was evaluated by examining treatment difference estimates with 95% confidence intervals.

RESULTS:

  Treatment with ERN/LRPT significantly improved LDL-C, HDL-C and TG levels compared with placebo/active comparator in each study cohort. These effects were generally consistent across all examined subgroups.

CONCLUSION:

Extended-release niacin/laropiprant represents an effective therapeutic option for the treatment of dyslipidemia across a range of patient types.

• Authors: H Bays, A Shah, Q Dong, C McCrary Sisk, D Maccubbin
• Journal: International journal of clinical practice (Int J Clin Pract) Vol. 65 Issue 4 Pg. 436-45 (Apr 2011) ISSN: 1742-1241 [Electronic] India
• PMID: 21401833 (Publication Type: Clinical Trial, Phase IV, Journal Article, Randomized Controlled Trial, Research Support, Non-U.S. Gov't)
• Copyright: © 2011 Blackwell Publishing Ltd.

Chemical References

• Cholesterol, HDL
• Cholesterol, LDL
• Delayed-Action Preparations
• Drug Combinations
• Hypolipidemic Agents
• Indoles
• MK-0524
• Triglycerides
• Niacin

Topics

• Adult
• Aged
• Cholesterol, HDL (metabolism)
• Cholesterol, LDL (metabolism)
• Coronary Disease (blood, etiology)
• Delayed-Action Preparations
• Double-Blind Method
• Drug Combinations
• Dyslipidemias (blood, drug therapy)
• Humans
• Hypolipidemic Agents (administration & dosage)
• Indoles (administration & dosage)
• Male
• Middle Aged
• Niacin (administration & dosage)
• Risk Factors
• Treatment Outcome
• Triglycerides (metabolism)